These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17988560)

  • 21. Molecular mechanisms of muscle atrophy.
    McKinnell IW; Rudnicki MA
    Cell; 2004 Dec; 119(7):907-10. PubMed ID: 15620349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation.
    Aliverti A; Macklem PT
    J Appl Physiol (1985); 2008 Aug; 105(2):763. PubMed ID: 18678629
    [No Abstract]   [Full Text] [Related]  

  • 23. Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation.
    Debigaré R; Maltais F
    J Appl Physiol (1985); 2008 Aug; 105(2):764. PubMed ID: 18678630
    [No Abstract]   [Full Text] [Related]  

  • 24. Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation.
    O'Donnell D; Webb K
    J Appl Physiol (1985); 2008 Aug; 105(2):765. PubMed ID: 18678631
    [No Abstract]   [Full Text] [Related]  

  • 25. Is there a common mechanism linking muscle wasting in various disease types?
    Tisdale MJ
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):287-92. PubMed ID: 18685377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profiling of mRNA expression in quadriceps of patients with COPD and muscle wasting.
    Debigaré R; Maltais F; Côté CH; Michaud A; Caron MA; Mofarrahi M; Leblanc P; Hussain SN
    COPD; 2008 Apr; 5(2):75-84. PubMed ID: 18415806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myostatin dysfunction does not protect from fasting-induced loss of muscle mass in mice.
    Fokin A; Minderis P; Venckunas T; Lionikas A; Kvedaras M; Ratkevicius A
    J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):342-353. PubMed ID: 31475942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscle wasting in chronic obstructive pulmonary disease: to bother and to measure!
    Wouters EF
    Am J Respir Crit Care Med; 2006 Jan; 173(1):4-5. PubMed ID: 16368791
    [No Abstract]   [Full Text] [Related]  

  • 29. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease.
    Jagoe RT; Engelen MP
    Eur Respir J Suppl; 2003 Nov; 46():52s-63s. PubMed ID: 14621107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrathoracic muscle wasting in exacerbations of COPD: no longer outside the region of interest.
    Greening NJ; Polkey MI; McAuley HJC
    Thorax; 2021 Jun; 76(6):530-531. PubMed ID: 33574120
    [No Abstract]   [Full Text] [Related]  

  • 31. Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia.
    Favier FB; Costes F; Defour A; Bonnefoy R; Lefai E; Baugé S; Peinnequin A; Benoit H; Freyssenet D
    Am J Physiol Regul Integr Comp Physiol; 2010 Jun; 298(6):R1659-66. PubMed ID: 20237300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscle wasting: a crosstalk between protein synthesis and breakdown signalling.
    Attaix D; Baracos VE; Pichard C
    Curr Opin Clin Nutr Metab Care; 2012 May; 15(3):209-10. PubMed ID: 22466927
    [No Abstract]   [Full Text] [Related]  

  • 33. Myostatin: Regulator of muscle wasting in heart failure and treatment target for cardiac cachexia.
    Springer J; Adams V; Anker SD
    Circulation; 2010 Jan; 121(3):354-6. PubMed ID: 20065169
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic obstructive pulmonary disease. 5: systemic effects of COPD.
    Wouters EF
    Thorax; 2002 Dec; 57(12):1067-70. PubMed ID: 12454303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory factors in age-related muscle wasting.
    Roth SM; Metter EJ; Ling S; Ferrucci L
    Curr Opin Rheumatol; 2006 Nov; 18(6):625-30. PubMed ID: 17053510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease.
    Piehl-Aulin K; Jones I; Lindvall B; Magnuson A; Abdel-Halim SM
    Respiration; 2009; 78(2):191-6. PubMed ID: 19270439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muscle atrophy is not always sarcopenia.
    Hepple RT
    J Appl Physiol (1985); 2012 Aug; 113(4):677-9. PubMed ID: 22518833
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular mechanisms and treatment options for muscle wasting diseases.
    Rüegg MA; Glass DJ
    Annu Rev Pharmacol Toxicol; 2011; 51():373-95. PubMed ID: 20936944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.
    Barreiro E; Gea J
    Chron Respir Dis; 2016 Aug; 13(3):297-311. PubMed ID: 27056059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF alpha receptor genotype influences smoking-induced muscle-fibre-type shift and atrophy in mice.
    De Paepe B; Brusselle GG; Maes T; Creus KK; D'hose S; D'Haese N; Bracke KR; D'hulst AI; Joos GF; De Bleecker JL
    Acta Neuropathol; 2008 Jun; 115(6):675-81. PubMed ID: 18309502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.